Baillie Gifford & Co. Has $173.42 Million Position in Penumbra, Inc. (NYSE:PEN)

Baillie Gifford & Co. raised its stake in shares of Penumbra, Inc. (NYSE:PEN) by 23.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 730,233 shares of the company’s stock after buying an additional 138,387 shares during the quarter. Baillie Gifford & Co.’s holdings in Penumbra were worth $173,416,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of PEN. True Wealth Design LLC bought a new position in shares of Penumbra during the 3rd quarter valued at about $26,000. UMB Bank n.a. lifted its stake in Penumbra by 57.4% in the 4th quarter. UMB Bank n.a. now owns 192 shares of the company’s stock valued at $46,000 after acquiring an additional 70 shares in the last quarter. Mather Group LLC. lifted its stake in Penumbra by 208.0% in the 4th quarter. Mather Group LLC. now owns 308 shares of the company’s stock valued at $73,000 after acquiring an additional 208 shares in the last quarter. Advisors Asset Management Inc. lifted its stake in Penumbra by 11.5% in the 3rd quarter. Advisors Asset Management Inc. now owns 416 shares of the company’s stock valued at $81,000 after acquiring an additional 43 shares in the last quarter. Finally, Blue Trust Inc. increased its position in shares of Penumbra by 808.9% during the 3rd quarter. Blue Trust Inc. now owns 509 shares of the company’s stock worth $92,000 after purchasing an additional 453 shares during the last quarter. Institutional investors own 88.88% of the company’s stock.

Wall Street Analysts Forecast Growth

PEN has been the topic of several recent analyst reports. UBS Group initiated coverage on Penumbra in a research report on Tuesday, January 21st. They set a “buy” rating and a $305.00 price target on the stock. Oppenheimer assumed coverage on Penumbra in a report on Tuesday, December 17th. They set an “outperform” rating and a $275.00 target price on the stock. Wells Fargo & Company raised Penumbra from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $190.00 to $275.00 in a report on Wednesday, December 11th. Canaccord Genuity Group upped their target price on Penumbra from $260.00 to $323.00 and gave the company a “buy” rating in a research report on Monday, December 9th. Finally, Citigroup upped their target price on Penumbra from $220.00 to $245.00 and gave the company a “neutral” rating in a research report on Wednesday, December 11th. Four research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $261.36.

Insider Buying and Selling at Penumbra

In related news, CEO Adam Elsesser sold 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $237.28, for a total transaction of $3,559,200.00. Following the completion of the sale, the chief executive officer now owns 852,582 shares of the company’s stock, valued at $202,300,656.96. This trade represents a 1.73 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Johanna Roberts sold 600 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $244.49, for a total value of $146,694.00. Following the sale, the executive vice president now directly owns 63,444 shares of the company’s stock, valued at $15,511,423.56. This represents a 0.94 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 33,219 shares of company stock worth $7,985,639. 5.00% of the stock is currently owned by insiders.

Penumbra Price Performance

Penumbra stock opened at $267.83 on Monday. The company has a current ratio of 5.82, a quick ratio of 3.25 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $10.28 billion, a PE ratio of 311.43, a P/E/G ratio of 1.92 and a beta of 0.53. Penumbra, Inc. has a 12 month low of $148.00 and a 12 month high of $277.89. The stock has a 50-day moving average price of $255.04 and a two-hundred day moving average price of $224.21.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.